Zimmer Biomet Holdings, Inc.

ZBH

US98956P1021

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 04:00:02 2024-05-10 pm EDT			5-day change	1st Jan Change
121.3 ^USD	-0.11%		-0.29%	-0.32%

May. 03	Raymond James Adjusts Price Target on Zimmer Biomet Holdings to $138 From $142	MT
May. 03	UBS Adjusts Price Target on Zimmer Biomet Holdings to $112 From $109, Maintains Sell Rating	MT

Zimmer Biomet Holdings, Inc. Provides Earnings Guidance for the Full Year Ending December 31, 2022

February 07, 2022 at 09:15 am EST

Zimmer Biomet Holdings, Inc. provided earnings guidance for the full year ending December 31, 2022. For the period, the company projected Revenue to be $1 billion.

Latest news about Zimmer Biomet Holdings, Inc.

Raymond James Adjusts Price Target on Zimmer Biomet Holdings to $138 From $142	May. 03	MT
UBS Adjusts Price Target on Zimmer Biomet Holdings to $112 From $109, Maintains Sell Rating	May. 03	MT
Truist Adjusts Zimmer Biomet Holdings' PT to $130 From $137, Keeps Hold Rating	May. 03	MT
Bernstein Adjusts Price Target on Zimmer Biomet to $133 From $132	May. 03	MT
Jefferies Adjusts Price Target on Zimmer Biomet to $135 From $136	May. 03	MT
Citigroup Adjusts Price Target on Zimmer Biomet to $134 From $140	May. 03	MT
Morgan Stanley Adjusts Price Target on Zimmer Biomet to $130 From $135	May. 03	MT
Jefferies Adjusts Zimmer Biomet Price Target to $135 From $136	May. 03	MT
Citigroup Adjusts Zimmer Biomet Price Target to $134 From $140	May. 03	MT
Morgan Stanley Adjusts Zimmer Biomet Price Target to $130 From $135	May. 03	MT
Oppenheimer Adjusts Price Target on Zimmer Biomet Holdings to $155 From $150	May. 03	MT
BTIG Adjusts Price Target on Zimmer Biomet to $139 From $138, Keeps Buy Rating	May. 02	MT
Transcript : Zimmer Biomet Holdings, Inc., Q1 2024 Earnings Call, May 02, 2024	May. 02
Zimmer Biomet beats Q1 profit estimates on robust demand for knee, hip devices	May. 02	RE
Zimmer Biomet Holdings Q1 Adjusted Earnings, Net Sales Rise; 2024 Outlook Reiterated	May. 02	MT
(ZBH) ZIMMER BIOMET HOLDINGS Expects Fiscal Year 2024 EPS Range $8.00 - $8.15	May. 02	MT
Earnings Flash (ZBH) ZIMMER BIOMET HOLDINGS Reports Q1 Revenue $1.89B, vs. Street Est of $1.87B	May. 02	MT
Earnings Flash (ZBH) ZIMMER BIOMET HOLDINGS Posts Q1 EPS $1.94, vs. Street Est of $1.87	May. 02	MT
Zimmer Biomet Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Zimmer Biomet Holdings, Inc. Reiterates Financial Guidance for Current Full-Year 2024	May. 02	CI
North American Morning Briefing : Stock Futures -2-	May. 02	DJ
Truist Securities Adjusts Zimmer Biomet Price Target to $137 From $135, Hold Rating Kept	Apr. 15	MT
Zimmer Biomet Partners with Three Pickleball Organizations in US	Apr. 04	MT
Citigroup Raises Price Target on Zimmer Biomet to $140 From $134, Keeps Neutral Rating	Apr. 03	MT
3M Board Approves Healthcare Unit Spinoff -- Update	Mar. 08	DJ

Chart Zimmer Biomet Holdings, Inc.

Duration

Period

More charts

Zimmer Biomet Holdings, Inc. specializes in designing, manufacturing, and selling orthopedic and dental reconstruction implants, spinal implants, and traumatology products. Net sales break down by family of products as follows: - reconstruction implants (57.5%): knees replacement (58.8% of net sales), hips replacement (41.2%); - surgical products and traumatology equipment (22.1%); - dental, spinal and craniomaxillofacial implants (12.8%); - other (7.6%): primarily orthopedic surgery materials and instruments used during post-operative rehabilitation. At the end of 2021, the group had approximately 30 production sites worldwide. Net sales are distributed geographically as follows: Americas (61.3%), Europe/Middle East/Africa (21.3%) and Asia/Pacific (17.4%).

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-29 - Investor Day

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Zimmer Biomet Holdings, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

121.3 USD

Average target price

136.6 USD

Spread / Average Target

+12.61%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ZIMMER BIOMET HOLDINGS, INC.	-0.32%	24.96B
ABBOTT LABORATORIES	-4.84%	182B
MEDTRONIC PLC	+0.56%	110B
BECTON, DICKINSON AND COMPANY	-3.35%	68.11B
DEXCOM, INC.	+2.39%	50.53B
CENCORA, INC.	+9.36%	44.8B
HOYA CORPORATION	+2.70%	40.7B
WEST PHARMACEUTICAL SERVICES, INC.	+3.43%	26.53B
TERUMO CORPORATION	+13.67%	25.02B
STERIS PLC	+5.22%	22.86B

Other Medical Equipment, Supplies & Distribution